

History

Foundation 1991

Our success story

The company was founded in 1991 by Dr. Stefan Wissel and Professor Dr. Hanns Häberlein in Rheinzabern in the Southern Palatinate – at that time under the name HWI ANALYTIK.

The first letters of the names Häberlein and Wissel gave rise to the name HWI. The addition “Analytik” describes the young entrepreneurs’ focus of activities at that time, which lay on the processing of analytical issues for medicinal products and related products as well as enzyme isolation and purification .

HWI offers a wide range of innovative technologies and services for pharma and biotech at 3 sites in Germany.

Frankfurt Site


- Drug development
- Semi-solid and liquid formulations (including parenteral, intranasal)
- Small batches and clinical trial manufacturing

Ruelzheim Site

- Laboratory services
- Pharmacovigilance
- QP services & regulatory services

Appenweier Site

- Drug development
- Solid formulations
- Small batches and clinical trial manufacturing





1991 Foundation of HWI ANALYTIK GmbH in Rheinzabern.

1993 4 employees, first full-time employee.

1995 Business relocation within the Rheinzabern site: Relocation to new GMP laboratories and offices on the premises of Rats-Apotheke. Extension of services for the qualification of pharmaceutical reference standards. Establishment of a laboratory unit for isolation and purification of natural products from medicinal plants, 8 employees.

1997 Expansion of the Rheinzabern site with further offices, training facilities and communal rooms.


1998 Extension of services for regulatory affairs, 20 employees.

2000 Expansion of GMP laboratory by new building.

2001 Expansion of services for medicinal products and cosmetics toxicology.

2003 Business expansion: Relocation of the Isolation of Natural Products Department to a second site in Römerbadstraße, Rheinzabern, 30 employees.

2004 Business expansion: Relocation of GMP laboratory from Rheinzabern to Rülzheim. Rental of Hall 1 with approx. 400 m² laboratory space. 40 employees.



2005 Extension of services for pharmacovigilance and toxicology.

2006 Foundation of i.DRAS GmbH in Planegg/Martinsried. Relocation of drug regulatory affairs services from HWI to i.DRAS.

2007 Purchase of further 6,000 m² adjacent premises in Rülzheim. Capacity expansion of GMP laboratory and pharmacovigilance. 50 employees.

2008 Foundation of Sercona GmbH (Appenweier) by takeover of the department for formulation development of medicinal products from a CMO with 25 employees. Purchase of the pharmaceutical laboratory LAZ from Prof. Dr. Hamacher in Tübingen. Capacity expansion of GMP laboratory in Rülzheim.

2008 Relocation of company headquarters of HWI ANALYTIK from Rheinzabern to Rülzheim. 65 employees (HWI ANALYTIK).

2009 Completion of the new administration building at the Rülzheim site. Relocation of the administrative department from Rheinzabern to Rülzheim. Expansion of GMP laboratory in Rülzheim (hall 2). Relocation of the Laboratory for the Isolation of Natural Products from Rheinzabern to Rülzheim. Extension of services for pharmacovigilance and quality.

2012 LAZ GmbH & Co. KG is integrated into HWI ANALYTIK GmbH, supplementing the service spectrum in the business unit Laboratory Services. The business site in Tübingen continues to exist.



2015

Purchase of previously rented premises of Rheinzaberger Straße 8 in Rülzheim. Establishment of the brand HWI group. 130 employees.

2016

Change of corporate name of HWI ANALYTIK GmbH to HWI pharma services GmbH and that of Sercona GmbH to HWI development GmbH.

2017

Relocation of HWI's Tübingen site to Rülzheim.

2019

Purchase of further 400 m² adjacent premises in Rülzheim. 150 employees. Change of corporate name of i.DRAS GmbH to HWI regulatory services GmbH. HWI receives funding from the programme Artificial Intelligence as a Driver for Economically Relevant Ecosystems for the project: Digital Vigilance Services - software solutions (neural networks).

2020

HWI group takes over the Frankfurt development site of Losan Pharma GmbH. HWI is thus further developing its strategy towards high potent active ingredients and sterile dosage forms. HWI receives funding from the Innovation and Technology Support Programme (Inno-Top) Rhineland-Palatinate for the project: Establishment of an innovative screening and technology platform for the fast, flexible and cost-efficient development and production of parenteral (sterile) drug formulations for poorly soluble chemical and biological agents through further development of nanotechnology.

2021

Expansion of analytical and technological services to large molecules and to the development of nasal formulations; first development of a nasal spray with microsuspension and nanosuspension of a poorly soluble active ingredient.



2022

Successful completion of the funding project as part of the InnoTop funding program.

2023

Successful completion of the funding project as part of the Artificial Intelligence as a Driver for Economically Relevant Ecosystems funding program.



Dr. Stefan Wissel



Dr. Philipp Wissel

Our purpose is to discover new ways to improve and extend people's lives.

With novel technologies and innovative services, we aim to advance the development of highly effective medicines for everyone.